清华系AI黑马融资5亿！ | 融资周报（2025年第44期）

Financing Overview - A total of 27 financing events occurred in Shanghai this week, with 13 disclosing amounts totaling approximately 1.753 billion yuan [5][10] - The majority of financing events took place in the Pudong New Area, with 12 events, followed by Minhang District with 5 events [5] - The most common financing round was Series A, with 11 occurrences, followed by angel rounds with 8 [7] Company Dynamics - Weike Bio's patent for a detection method based on exogenous DNA insertion mutations was approved on November 5 [3] - DeYin Technology showcased at the Hong Kong Elderly Technology Expo on November 20 [3] - Hejian Technology and CAE Network partnered to establish a PCB design and digital chip simulation collaboration on December 1 [3] Hot Industry Focus - The National Medical Products Administration approved a disposable pressure monitoring cardiac pulsed electric field ablation catheter from Shanghai MicroPort on November 24 [4] - Novartis' innovative drug, Ripretinib tablets, received approval from the National Medical Products Administration on November 26 [4] - Anke Bio's Shanghai Innovation Research Institute and Shanghai Anke Huaze Pharmaceutical officially opened in Zhangjiang on November 27 [4][24] Notable Financing Events - Wunwen Qinqu completed nearly 500 million yuan in Series A+ financing on November 27, led by Zhuhai Technology Group and Futen Capital [13][14] - Hypershell completed 70 million USD in Pre-B and B round financing on November 27, with participation from various investors [16][17] - Kaisi Kedi completed 300 million yuan in Series B financing on November 28, led by Guotou Xiandao [18][19] - Aoyi Technology completed over 100 million yuan in B+++ round financing on November 28, exclusively invested by listed company Redik [20][21] - Kaiwuji completed a 100 million yuan angel round financing on November 26, led by IDG Capital and BlueRun Ventures [22][23] Policy and Regulatory Developments - The Shanghai government introduced 22 measures to support the high-quality development of the biopharmaceutical industry, focusing on innovation and regulatory reforms [25]